诱导共刺激因子在癌症免疫治疗中的作用  

Role of Inducible Co-Stimulator in Cancer Immunotherapy

作　　者：丁剑兰 陈乐乐 刘谷一 周宏祎 孙江涛[1] DING Jianlan;CHEN Lele;LIU Guyi;ZHOU Hongyi;SUN Jiangtao(The First Affiliated Hospital,and College of Clinical Medicine of Henan University of Science and Technology,Luoyang,China,471003)

机构地区：[1]河南科技大学临床医学院,河南科技大学第一附属医院,中国洛阳471003

出　　处：《食管疾病》2023年第3期220-225,共6页Journal of Esophageal Diseases

摘　　要：食管癌作为全世界最常见的恶性肿瘤之一,其发病率、死亡率均较高。除了传统的手术、化疗、放疗等治疗手段外,免疫治疗具有较好的疗效。通过靶向共刺激B7超家族成员,诱导共刺激因子(inducible co-stimulator,ICOS)在T细胞上的表达来促进抗肿瘤反应,近年来引起了转化医学界的关注。本研究使用关键词“ICOS”和“癌症”进行了广泛的检索和分析,发现ICOS在不同恶性肿瘤的发生中具有双重作用,并总结了目前关于免疫治疗靶向ICOS/ICOSL通路的研究现状。Esophageal cancer,one of the most common malignancies worldwide,has a high morbidity and mortality rate.In addition to traditional surgery,chemotherapy,and radiotherapy,immunotherapy has shown good efficacy.Targeting co-stimulatory B7 superfamily members to promote antitumor response has emerged as a new approach in cancer immunotherapy.Inducible co-stimulator(ICOS),expressed on activated T cells,has gained interest in the translational medicine community.We conducted an extensive literature review using the keywords“ICOS”and“cancer”.In this review,we highlight the dual role of ICOS in oncogenesis in different malignancies and summarize the current knowledge about targeting the ICOS/ICOSL pathway with immunotherapies.

关 键 词：ICOS/ICOSL 食管癌 免疫治疗 

分 类 号：R735.1[医药卫生—肿瘤]